12/13
08:04 am
algs
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
12/13
08:00 am
algs
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/26
08:06 am
algs
Aligos Therapeutics to Present at Investor Conferences in December [Yahoo! Finance]
Medium
Report
Aligos Therapeutics to Present at Investor Conferences in December [Yahoo! Finance]
11/26
08:00 am
algs
Aligos Therapeutics to Present at Investor Conferences in December
Medium
Report
Aligos Therapeutics to Present at Investor Conferences in December
11/19
01:30 pm
algs
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
High
Report
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
11/7
08:36 am
algs
Aligos Therapeutics, Inc. (NASDAQ: ALGS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
High
Report
Aligos Therapeutics, Inc. (NASDAQ: ALGS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
11/6
07:28 pm
algs
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
High
Report
Aligos Therapeutics, Inc. (ALGS) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/6
04:05 pm
algs
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
Medium
Report
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
10/30
04:05 pm
algs
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
Low
Report
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
10/23
08:18 am
algs
Aligos Therapeutics, Inc. (NASDAQ: ALGS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Low
Report
Aligos Therapeutics, Inc. (NASDAQ: ALGS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
10/22
09:04 am
algs
Aligos Therapeutics up on FDA clearance of IND application for its Hepatitis B treatment [Seeking Alpha]
Medium
Report
Aligos Therapeutics up on FDA clearance of IND application for its Hepatitis B treatment [Seeking Alpha]
10/22
08:00 am
algs
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
Medium
Report
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
10/15
09:00 am
algs
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
Low
Report
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
10/11
08:00 am
algs
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/1
08:00 am
algs
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
Low
Report
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
9/30
08:00 am
algs
Aligos Therapeutics to Present at Investor Conferences in October
Medium
Report
Aligos Therapeutics to Present at Investor Conferences in October